Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Oct 13;5(10):e13281.
doi: 10.1371/journal.pone.0013281.

Chloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in Madagascar

Affiliations
Multicenter Study

Chloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in Madagascar

Valérie Andriantsoanirina et al. PLoS One. .

Abstract

Molecular studies have demonstrated that mutations in the Plasmodium falciparum chloroquine resistance transporter gene (Pfcrt) play a major role in chloroquine resistance, while mutations in P. falciparum multidrug resistance gene (Pfmdr-1) act as modulator. In Madagascar, the high rate of chloroquine treatment failure (44%) appears disconnected from the overall level of in vitro CQ susceptibility (prevalence of CQ-resistant parasites <5%) or Pfcrt mutant isolates (<1%), strongly contrasting with sub-Saharan African countries. Previous studies showed a high frequency of Pfmdr-1 mutant parasites (>60% of isolates), but did not explore their association with P. falciparum chloroquine resistance. To document the association of Pfmdr-1 alleles with chloroquine resistance in Madagascar, 249 P. falciparum samples collected from patients enrolled in a chloroquine in vivo efficacy study were genotyped in Pfcrt/Pfmdr-1 genes as well as the estimation of the Pfmdr-1 copy number. Except 2 isolates, all samples displayed a wild-type Pfcrt allele without Pfmdr-1 amplification. Chloroquine treatment failures were significantly associated with Pfmdr-1 86Y mutant codon (OR = 4.6). The cumulative incidence of recurrence of patients carrying the Pfmdr-1 86Y mutation at day 0 (21 days) was shorter than patients carrying Pfmdr-1 86N wild type codon (28 days). In an independent set of 90 selected isolates, in vitro susceptibility to chloroquine was not associated with Pfmdr-1 polymorphisms. Analysis of two microsatellites flanking Pfmdr-1 allele showed that mutations occurred on multiple genetic backgrounds. In Madagascar, Pfmdr-1 polymorphism is associated with late chloroquine clinical failures and unrelated with in vitro susceptibility or Pfcrt genotype. These results highlight the limits of the current in vitro tests routinely used to monitor CQ drug resistance in this unique context. Gaining insight about the mechanisms that regulate polymorphism in Pfmdr1 remains important, particularly regarding the evolution and spread of Pfmdr-1 alleles in P. falciparum populations under changing drug pressure which may have important consequences in terms of antimalarial use management.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flowchart of patients.
Flowchart of patients: Enrollment, Randomization, Follow-up, Molecular genotyping.
Figure 2
Figure 2. Prevalence of the two microsatellite loci flanking Pfmdr-1 gene.
Distribution and prevalence of the two microsatellite loci flanking Pfmdr-1 gene (MS 956456, panel A and MS 957861, panel B) in 53 Plasmodium falciparum isolates collected from Madagascar in 2006–2007.
Figure 3
Figure 3. Parasites curves following CQ-treatment according Pfmdr-1 alleles.
Asexual parasites curves following CQ-treatment according Pfmdr-1 mutation at position 86 in isolates from patients included in the analysis, Madagascar in 2006–2007.
Figure 4
Figure 4. Curves of cumulative incidence of recurrence of patients over the 28-day follow-up period.
Kaplan-Meier curves of cumulative incidence of recurrence of patients over the 28-day follow-up period according Pfmdr-1 mutation at position 86 in isolates of day of recurrence from patients included in the analysis, Madagascar in 2006–2007.

References

    1. Talisuna AO, Bloland P, D'Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev. 2004;17:235–254. - PMC - PubMed
    1. Wellems TE, Hayton K, Fairhurst RM. The impact of malaria parasitism: from corpuscles to communities. J Clin Invest. 2009;119:2496–2505. - PMC - PubMed
    1. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature. 2002;418:320–323. - PubMed
    1. Rowe AK, Rowe SY, Snow RW, Korenromp EL, Schellenberg JR, et al. The burden of malaria mortality among African children in the year 2000. Int J Epidemiol. 2006;35:691–704. - PMC - PubMed
    1. Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol. 2001;17:593–597. - PubMed

Publication types

MeSH terms